Noncompliance to long-term medical therapy is a well-known problem among patients treated for ulcerative colitis, but studies of long-term consequences in unselected patients are lacking. The authors aimed to determine the risk of recurrence according to long-term compliance with oral 5-aminosalicylic acid among unselected patients with ulcerative colitis.
The authors conducted a 7-year follow-up study of a population-based inception cohort of 243 Danish patients with ulcerative colitis diagnosed from 2003 to 2004. Compliance was defined as consumption of ≥80% of prescribed oral 5-aminosalicylic acid. Data were collected from medical records and the Danish National Prescription Database. They performed Cox regression analysis with adjustments for demographic and clinical characteristics to examine risk of recurrence (defined by increased use of oral 5-Aminosalicylic Acid, other additional treatment, or colectomy) in compliant versus noncompliant patients.
In total, 182 patients (75%) experienced at least 1 recurrence during follow-up. For the first year after diagnosis, risk of recurrence did not differ significantly between compliant and noncompliant patients. For 1 to 3 years (hazard ratio: 0.46, 95% CI, 0.33–0.63) and 3 to 8 years (hazard ratio: 0.42, 95% CI, 0.32–0.55) after diagnosis, risk of recurrence was significantly decreased among noncompliant patients compared with that of compliant patients.
This unselected cohort study revealed a reverse association between compliance and recurrence of ulcerative colitis. This is unlikely to be explained by severe confounding because the authors were able to adjust for several demographic and clinical factors. Results may instead reflect that patients during recurrence-free periods through self-management choose not to take their medication.
Article first published online 28 January 2016.
*Gastrounit, Medical Section, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark;
†Department of Epidemiology Research, National Health Surveillance and Research, Copenhagen, Denmark; and
‡Department of Clinical Pharmacology, Rigshospitalet, Copenhagen, University of Copenhagen, Denmark.
Reprints: Michelle V. Prosberg, MD, Gastrounit, Medical Section, Hvidovre Hospital, Kettegaard Allé 30, DK-2650 Hvidovre, Denmark (e-mail: firstname.lastname@example.org).
Grant support was achieved from the Research Council of the Capital Region of Denmark, Vibeke Binder & Povl Riis' Foundation, Denmark, Colitis-Crohn Foundation of Denmark (CCF), Beckett Foundation, Denmark, Aase & Ejnar Danielsen's Foundation, Denmark and Tillotts Pharma AG, Denmark. The study sponsors did not contribute to the study design, analysis or interpretation of the data, or publication.
F. Bendtsen reports grants from Novo Nordisk, personal fees from Intercept, grants and personal fees from Norgine, personal fees from Takeda, outside the submitted work. The other authors have no conflicts of interest to disclose.
Received November 10, 2015
Accepted November 17, 2015